Downregulation of Human Toll-like Receptor 2 and 4 Genes in Inactive Carriers of Hepatitis B Virus Infection-A Possible Mode of Viral Persistence

Aparna Jakkampudi, RM Mukherjee, Ramya Kota, Gelli Veena Shravanti, PN Rao, DN Reddy

ABSTRACT

AIM: Toll-like receptors (TLRs) although comprise an integral part of innate immune defense mechanism, role of TLRs in hepatitis B virus (HBV) mediated disease categories are sparsely studied. The aim of the present study was to assess host TLR2 and TLR4 gene expressions in various stages of HBV infection in relation to viral replication intermediate pregenomic RNA (pgRNA) in peripheral blood mononuclear cells (PBMCs) and HBV DNA concentration in sera.

METHODS: TLR2 and TLR4 mRNA expression in conjunction with pgRNA level in PBMCs of 65 treatment naïve HBV infected patients grouped in to acute (AHB), inactive carriers (IC), liver cirrhosis (Cirr) and hepatocellular carcinoma (HCC) were evaluated by reverse transcription polymerase chain reaction (RT-PCR) assay. Serum HBV DNA was measured by real time PCR assay. Thirty voluntary blood donors served as controls.

RESULTS: Compared to controls, TLR2 gene expression was significantly reduced in AHB (p<0.003), IC(p<0.006) and Cirr(p<0.01) while expression of TLR4 gene was significantly abridged in IC (p<0.0005) group only. A significantly higher elevation in the expression of TLR4 was noted in HCC (p<0.0001).

Despite having lower level of HBV DNA, ICs had substantial echelon of pgRNA comparable to other groups.

CONCLUSION: The results showed differential expression of TLR2 and TLR4 mRNA in HBV disease categories. On top, significant downregulation of both TLR2 and TLR4 expression was encountered in ICs only. This observation along with the level of viral pgRNA in ICs may well be indicative of dysregulation of one of the crucial arm of innate immune mechanism favoring long term persistence of the virus towards a chronic infection.

© 2014 ACT. All rights reserved.

Key words: Toll-like receptors; Gene expression; HBV infection; Inactive carriers; PBMC; pgRNA

INTRODUCTION

The human hepatitis B virus (HBV) chronically infects near about 360 million people worldwide with an annual mortality rate of about 1 million per year due to HBV-associated liver pathologies[3]. In spite of the noncytopathic nature of HBV, the spectrum of liver infection frequently proceed from chronic infection (CHB) to liver cirrhosis and development of hepatocellular carcinoma (HCC)[3]. Increased rate of CHB infection in neonates born from HBV infected mothers than adults indicate the role of a functionally mature immune system. The first line of defense against a pathogen is innate immunity, which slows the progress of infection and allows time for development of adaptive immunity.

At present, HBV has been shown to evade host innate immune system by downregulating the expression of several key proteins, including toll-like receptors (TLRs). TLRs are a family of pattern recognition receptors that play a crucial role in innate immune responses. Among the TLRs, TLR2 and TLR4 have been implicated in the mediation of HBV infection and disease progression.

In this study, we aimed to assess the expression of TLR2 and TLR4 genes in various stages of HBV infection, including acute hepatitis B (AHB), active carriers (AC), liver cirrhosis (Cirr), and hepatocellular carcinoma (HCC). The study was conducted in 65 treatment-naive HBV-infected patients, of whom 20 were acute hepatitis B patients, 30 were inactive carriers, 10 were liver cirrhosis patients, and 5 were patients with hepatocellular carcinoma. Thirty healthy volunteers served as controls.

The results showed a significant downregulation of TLR2 and TLR4 gene expression in inactive carriers (ICs) compared to healthy controls. The expression of TLR4 was found to be significantly higher in hepatocellular carcinoma (HCC) patients compared to other groups. Despite having a lower level of HBV DNA, ICs had a substantial echelon of pregenomic RNA (pgRNA) comparable to other groups.

These findings suggest a possible role of dysregulation of the innate immune mechanism in the long-term persistence of HBV infection. Further studies are needed to elucidate the mechanisms underlying this downregulation of TLR2 and TLR4 genes in ICs and to understand the implications for chronic HBV infection.
mechanisms while viral clearance is brought about by functional adaptive immune responses[9]. While a brisk and perpetual polyclonal cytotoxic T lymphocyte (CTL) response to HBV was observed in self resolved acute hepatitis patients, similar responses was significantly lesser or barely discernible in CHB patients[14,23]. Requirement of intrahepatic HBV-specific CD8+ T cells for viral clearance has been documented during acute HBV infection in chimpanzees[5]. In CHB, the variable outcome of liver disease has been ascribed either to the poor immune status of the host or HBV induced intonation of cell mediated immune response of the host[9].

Even though, HBV has been known to thwart the adaptive immune response of the host which is supposed to be activated by the virus itself[9], the precise role of the innate immune response in HBV infection is still not well understood. Study on the role of effective innate immune response in HBV infected subjects is further complicated because the patients are often diagnosed long after the onset of infection.

The family of Toll-like receptors (TLRs) as evolutionarily conserved pattern recognition receptors (PRRs) form a major component of the innate immune response by engaging themselves with various motifs of the pathogen associated molecular patterns (PAMPs). Despite the fact that TLRs can initiate innate immune cascades through the recognition of exogenous PAMPs, they also recognize endogenous signals released by damaged cells. This put up the possibility that immunopathology, initiated by a TLR mediated response to a PAMP, can protract tissue damage through other TLR-mediated mechanisms[9]. Induction of the antiviral state and production of type I Interferon (IFN α/β) can be mediated by TLRs[13]. As part of host’s antiviral defense mechanism, stimulation of TLRs initiates a MyD88 dependent(TLR2) or MyD88 independent (TLR4) signal transduction pathway leading to the release of inflammatory mediators/cytokines via activation of nuclear factor κB (NF-κB)[12]. Virus induced suppression of TLR mediated immune mechanism, thus, has a role in persistence of viral infection[11]. This has been corroborated further by the documented ability of HBV precore/hepatitis B secreted e-antigen (HBeAg) to interact and downregulate TLR-2 expression on hepatocytes[14]. In the presence of HBeAg, HBV has also been shown to down-regulate the expressions of TLR2 on monocytes (CD14+) from peripheral blood[11]. Significantly lower expression of TLR2 and TLR4 has been reported in PBMCs from CHB patients suggesting a possible interaction between HBsAg, TLR signaling and the innate immune responses[9].

Regardless of the above informations, no studies has been done so far about the expression of TLR 2 and TLR4 genes in HBV infected subjects having variable spectrum of liver diseases. Henceforth, the purpose of this study was to analyze the expression profile of PBMC derived TLR2 and TLR4 mRNAs from HBV infected subjects belong to different disease categories concerning their respective serum HBV DNA level and amount of HBV pregenomic RNA (pgRNA) as intracellular replication intermediate of the virus.

**METHODS**

Patients

Sixty five HBsAg positive treatment naïve subjects who attended the Asian Institute of Gastroenterology, Hyderabad, India during the period of January 2012 to September 2012 were enrolled in this study. Patients were further sorted out on the basis of past history, clinical presentations, anti-HBc IgM/IgG status, imaging data, liver histopathology, Child-Pugh(CP) scores[10] and as per the American association for the study of liver disease (AASLD) practice guidelines[21,24] into acute (AHB; n=14), inactive carriers (IC; n=23), cirrhosis (Cirr; n=13) and hepatocellular carcinoma (HCC; n=15) respectively. Patients co infected with HIV, HAV, HCV, HDV, or HEV were excluded from this study. A group of 30 healthy voluntary blood donors served as controls. Prior informed consents were taken from all the study subjects and the study protocol was approved by the institutional ethics committee.

**Serologic and biochemical parameters**

Serum aspartate transferase and alanine transferase levels were estimated by an automated clinical biochemistry analyzer (Randox,Oceanside, CA). The serum HBeAg and anti-HBe status of the subjects were ascertained by commercial enzyme-linked immunosorbent assay (ELISA) kits (Amar-EASE, Taiwan) as per the manufacturer’s instructions.

**HBV DNA quantitation**

HBV DNA was extracted from sera by the High Pure System Viral Nucleic Acid Kit (Roche Molecular Systems Inc, USA) as per manufacturer’s protocol. Amplification and quantitation of extracted HBV DNA as viral load was performed by Cobas® TaqMan® 48 Analyzer (Roche Diagnostics, USA) using real time Cobas® TaqMan® HBV test kit (Roche Molecular System, USA) as per manufacturer’s instructions.

**Isolation of total RNA from PBMCs**

PBMCs were immediately isolated from EDTA containing whole blood using histopaque-1077 (Sigma chemicals, USA) by recommended procedure. Total RNA was extracted from the isolated cells by Trizol (LifeTechnologies, USA) method and the extracted RNA was dissolved in diethyl pyrocarbonate (DEPC)-treated water.

**Preparation of cDNA**

Extracted RNA was subjected to reverse transcription reaction using random hexamers and MuLV-H reverse transcriptase (Fermentas Life Sciences, Germany) to generate a common cDNA pool. Prior to reverse transcription, 1 µg of total RNA was treated with 1 U of deoxyribonuclease (DNase I amplification grade, Gibco-BRL,USA) to remove all the contaminating DNA. The possibility of presence of traces of DNA was further ruled out by employing control reactions devoid of reverse transcriptase enzyme. RNA was reverse transcribed (60 min at 37°C) with 200 U of MMuLV reverse transcriptase (Fermentas Life Sciences, Germany) in 20 µL volume of 5×RT buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2) supplemented with 5 mM dithiothreitol (DDT), 0.5 mM deoxyribonucleoside triphosphates (dNTPs, Fermentas Life Sciences, Germany), 25 U ribonuclease inhibitor (Promega Corporation, Madison, WI, USA) and 200 ng random hexamers (Fermentas Life Sciences, Germany).

**Polymerase Chain Reaction (PCR) amplification of TLR2 and TLR4 genes**

Preceded by heating (95°C, 1 min) and quick-chilling on ice, an aliquot of 5 µL (0.3 µg) of the cDNA pool was used for PCR amplification in 50 µL of 10× buffer solution (100 mM Tris–HCl pH 9.3, 500 mM KCl, 1% Triton X-100) containing 0.08 mM dNTPs, forward and reverse primers (100 pM each), 1.5 mM MgCl2 and 2 U of Taq DNA polymerase (Fermentas Life Sciences, Germany). After initial denaturation at 94°C for 5 min, TLR2 and TLR4 cDNA
fragments were amplified by 30 cycles (95°C - 15s, 55°C - 30s & 72°C - 45s per step) followed by a final extension step at 72°C for 10min. For TLR2, the forward and reverse primers used were (5'-3') d (TTC TCA TCT CAC AAA ATT GCA AAT) and (GGA AGG TAA GTC CAG CAA AAT CT) respectively,[19] which yielded a product of 95bp. TLR4 cDNA fragments were amplified using forward and reverse primers (5'-3') d (CTG CAA TGG ATC AAG GAC CAG) and (TGC CCT GCT TAT CGG AGG GT) generating an amplicon of 81bp. Beta-actin as house keeping gene was amplified by 30 cycles (94°C - 30s, 58°C - 30s & 72°C - 30s per step), having an initial denaturation at 95°C for 5 min and final extension at 72°C for 10 min employing forward and reverse primers (5'-3') d (GCC TTA GAG TCT CCT GAG CA), and d (GAA GTT GGT TCT CTT CTA GG) as mentioned earlier.[21] The PCR product was finally clarified upon 2% agarose gel electrophoresis to resolve an amplicon of 364 bp after staining with ethidium bromide.

Upon capturing the gel image by Bio-Capt imazer (Vilber Lourmat, France), the integrated density of DNA band was evaluated by using the software Image J 1.42 (Broken Symmetry Software, USA) in respect to the known standard marker as a control with units nanogram permilliliters (ng/mL) and further normalized against the housekeeping gene beta actin used as internal control to define the expression of respective genes by the density of the band.[22]

Polymerase Chain Reaction Amplification of HBV Pregenomic RNA(pgRNA)

In order to ascertain the presence of replicating virus in PBMCs, reverse transcribed PgRNA cDNA fragments obtained from Trizol extracted PBMC derived total RNA were subjected to an amplification protocol of 40 cycles (94°C – 30 s, 58°C – 30 s & 72°C – 30 s per step) having an initial denaturation at 950C for 5 min and final extension at 72°C for 10 min employing forward and reverse primers (5'-3') d (TCT ACA ATG AGC TGC GTG TG) and d (GGA AGG TAA GTC CAG CAA AAT CT) generating an amplicon of 314 bp. Blank reactions without cDNA template were performed in all experiments as negative reaction control. Each amplified product (10 μl) was subjected to 2% agarose gel electrophoresis(100 V, 45 min) along with a 100 bp DNA ladder and visualized by UV fluorescence after staining with ethidium bromide.

Statistical analyses

Statistical significance for differences in gene expression between different groups was determined by descriptive statistics [mean, median, standard deviations, Inter Quartile Range(IQR)] and Student’s t-test, as and where applicable using the GraphPad Prism 3.0 software (GraphPad, San Diego, CA, USA). The two-tailed values of P<0.05 was considered statistically significant.

RESULTS

All the patients were adults (Mean age±SD=38.4±11.1 years) and consisted of 51 male and 14 females respectively. The detailed demographic, biochemical and virological characteristics of 65 patients assigned to different disease categories are shown in table 1. Control subjects had a mean±SD age of 32.7±10.2 years and consisted of 21 males and 9 females. None of the patients had compensated cirrhosis. All patients except those belonged to AHB group were negative for HBeAg but positive for anti HBe antibody indicating seroconversion.

Expression profile of TLR2 gene and TLR4 genes in control and patients

No significant changes observed in TLR2 expression between the control and patient groups (Figure 1). The observed median value of TLR4 in controls and patients were 0.538 (mean±SD=0.552±0.159, IQR=0.144) and 0.469 (mean ±SD=0.614±0.351, IQR=0.575) ng/mL respectively. Conversely, TLR2 gene expression was significantly reduced (p=0.005) in patients having median value of 0.44 (mean±SD=0.53±0.24, IQR=0.456) than the median value of 0.686 (mean±SD=0.69±0.29, IQR=0.314) ng/mL in controls respectively (Figure 1).

Comparative expression of TLR 2 gene in HBV disease categories

In comparison to controls (median=0.686; mean±SD=0.69±0.29, IQR=0.314), expression of TLR2 gene was significantly reduced (p=0.003) downgraded in AHB (median=0.41, mean±SD=0.43±0.16, IQR=0.213, p=0.003), IC (median=0.33, mean±SD=0.48±0.22, IQR=0.42, p=0.006) and cirrhosis group (median=0.40, mean±SD=0.45±0.19, IQR=0.256, p=0.01) respectively (Figure 2). However, an otherwise nonsignificant increase of TLR2 expression was noted in HCC group (median=0.81, mean±SD=0.76±0.23, IQR=0.160, p=0.4) than controls (Figure 2).

Comparative expression of TLR 4 gene in HBV disease categories

In respect to controls (median=0.538, mean±SD=0.55±0.15, IQR=0.144), significant downregulation (p=0.005) of TLR 4 expression was encountered in IC (median=0.37, mean ±SD=0.39±0.16, IQR=0.197) group only (Figure 3). No significant change in the expression of TLR 4 gene was noticed in AHB
IQR=0.289) than the controls as well as the other disease categories. The TLR 4 gene was seen in HCC (median=1.17, mean±SD=1.05±0.32, IQR=0.289) while in AHB, IC and cirrhosis group (median=0.466, mean±SD=0.57±0.26, IQR=0.401) weighed against controls (Figure 3). On the contrary, a significantly higher (p=0.0001) expression of TLR 4 gene was seen in HCC (median=1.17, mean±SD=1.05±0.32, IQR=0.289) than the controls as well as the other disease categories (Figure 3).

**Figure 4** Expression of HBV pgRNA among different disease groups (AHB – acute hepatitis B; IC – inactive carriers; CHB – chronic hepatitis B; Cirrhosis – cirrhosis of liver; HCC – hepatocellular carcinoma). The boxes represent the interquartile ranges, the whiskers indicate the ranges, and the center line in the box indicate the medians.

**DISCUSSION**

The immunological facets of importunate HBV infection have focused mainly on adaptive immunity, with petite research on the innate immune response to HBV[12]. The evolutionarily conserved family of pattern recognition toll-like receptors (TLRs) act as one of the crucial components of host mediated innate immune response. It has been described that PBMCs from patients with chronic HBV (CHB) infection express significantly lower levels of TLR2 and TLR4 mRNA transcripts compared with those from healthy donors[13]. TLR2 expression in peripheral monocytes were shown to reduced in patients with HBeAg+ CHB[13]. While HBV mediated downregulation of the expression of TLR2 is considered as a means to alter the innate immune response in CHB infection[13], it has been reported that the expression of TLR2 is regulated by the precore protein in CHB, and that there was significant reduction in cytokine production (TNF-alfa) and phospho-p38 kinase expression in the presence of HBeAg[23]. Furthermore, co localization of HBeAg with the Toll/IL-1-receptor-(TIR-) containing proteins translocating chain-associating membrane (TRAM) protein, myelin and lymphocyte protein (MAL) and TLR at the subcellular level has been shown to be able to disrupt TIR: TIR interaction critical for TLR-mediated signaling[24]. Inhibitory effect of HBsAg on TLR2 signalling pathway through selective inhibition of TLR2 ligand Pam3csk4 has also been shown in PBMCs of CHB patients[25].

Till now, data regarding the expression of TLR2 and TLR4 are mainly available in CHB patients and not been able to address the issue in inactive carriers (IC) of the disease which form the major group of CHB subjects. In this setting, our study for the first time, showed that whilst the expression of TLR2 was manifestly reduced in AHB, IC and cirrhosis group in comparison to controls, TLR4 gene expression was significantly suppressed in IC group only insinuating subsistence of different regulatory mechanism in this arm of innate immunity in diverse phases of HBV infection. It is known that while the TLR2 activation takes place through the instigation of the adaptor protein MyD88, the TLR4 signalling pathway can operate without the involvement of MyD88. In this process, the TLR2 activation takes place through the instigation of the adaptor protein MyD88. In this process, the TLR2 activation takes place through the instigation of the adaptor protein MyD88, the TLR4 signalling pathway can operate without the involvement of MyD88. The immunological facets of importunate HBV infection have focused mainly on adaptive immunity, with petite research on the innate immune response to HBV[12]. The evolutionarily conserved family of pattern recognition toll-like receptors (TLRs) act as one of the crucial components of host mediated innate immune response. It has been described that PBMCs from patients with chronic HBV (CHB) infection express significantly lower levels of TLR2 and TLR4 mRNA transcripts compared with those from healthy donors[13]. TLR2 expression in peripheral monocytes were shown to reduced in patients with HBeAg+ CHB[13]. While HBV mediated downregulation of the expression of TLR2 is considered as a means to alter the innate immune response in CHB infection[13], it has been reported that the expression of TLR2 is regulated by the precore protein in CHB, and that there was significant reduction in cytokine production (TNF-alfa) and phospho-p38 kinase expression in the presence of HBeAg[23]. Furthermore, co localization of HBeAg with the Toll/IL-1-receptor-(TIR-) containing proteins translocating chain-associating membrane (TRAM) protein, myelin and lymphocyte protein (MAL) and TLR at the subcellular level has been shown to be able to disrupt TIR: TIR interaction critical for TLR-mediated signaling[24]. Inhibitory effect of HBsAg on TLR2 signalling pathway through selective inhibition of TLR2 ligand Pam3csk4 has also been shown in PBMCs of CHB patients[25].
antiviral protein IFN-β through escalation of IRF-3. It appears that in AHB, IC and cirrhotics, the viral modulation of proinflammatory cytokines through suppression of TLR2 is more pronounced to inhibit inflammatory process which might not be favourable for the virus. In this milieu, noteworthy repression of TLR4 genes observed only in IC group in our study might have implications since it can inhibit the production of specific anti viral proteins like interferon favoring viral persistence. Despite having lower level of serum HBV DNA, the IC group depicted substantial amount of pgRNA comparable to other groups indicative of intracellular replication activity of the virus. This observation is in accord with our recent pronouncement of higher level of pgRNA alongwith downregulation of DNA damage repair genes raising the possibility of diversion of the viral replication pathway towards integration of viral DNA in to host genome. Since the IC group in our study were devoid of HBeAg and seroconverted to anti HBe positivity, involvement of other HBV proteins/epitopes antagonizing TLR4 expression has to be worked out. Based on the notions that TLR agonists were strong candidates to activate and modulate the impaired immune responses instigated by HBV proteins, early therapeutic intervention using such agonists might appear beneficial to impede viral persistence towards the establishment of chronic infection.

In our study, the TLR4 expression was seen to be drastically enhanced in HCC but not in any other disease categories. Similar observations has been reported by others in HCC, although, not enhanced in HCC but not in any other disease categories. Similar observations have been reported by others in HCC, although, not mediated by HBV, suggesting the role of TLR2 and TLR4 signaling in the course of HCC development. Role of TLRs promoting liver tumorigenesis through expression of cytokine and hepatomitogens mainly in myeloid cells has also been implicated. Furthermore, a marked decrease in the incidence, size, and number of chemically induced liver cancer tumors was noticed in mice deficient in TLR4 and MyD88, but not with TLR2, thus, indicative of a strong input of TLR4 signaling in development of HCC. Our finding of reduced TLR4 expression in ICs also has some bearing with the previous report that the liver tissues from patients with severe CHB expressed higher level of TLR4 than those from patients with mild CHB. Since it is known that in absence of HBeAg, HBV replication is associated with activation of the TLR2 pathway, leading to increased TNFα production, while suppression of TLR4 results in a decreased production of proinflammatory cytokines, thus, demonstrating a potentially important interaction between HBV and the innate immune responses. Although the mechanism of HBV mediated repression of TLR4 in IC and elevation of the same in HCC is yet to be unravelled, further studies identifying the interfacing HBV proteins or the candidate TLR ligands regulating TLR4 expression ought to determine whether upregulation of TLR4 in ICs has the potential to be pondered as an overriding strategy to control HBV replication.

In conclusion, our data showed for the first time that the host TLR4 gene expression was drastically reduced in ICs of HBV infection but highly elevated in HCC where as TLR2 gene expression was markedly suppressed in AHB, IC and cirrhosis groups. Despite the lower viral load, level of HBV replication intermediate pgRNA in ICs was comparable to other disease groups. In view of the magnitude of TLR4 signaling as a part of innate antiviral defense mechanisms, repression of TLR4 gene in ICs may perhaps favor viral persistence in the host to expand chronic disease.

CONFLICT OF INTERESTS
There are no conflicts of interest with regard to the present study.

REFERENCES

23. Mukherjee RM, Shrvanathi GV, Jakkampudi A, Kota R, Jangala
Jakkampudi A et al. Suppression of TLR2 and 4 genes in inactive HBV carriers

1167 © 2014 ACT. All rights reserved.